Boston Scientific Corporation (BSX)
What changed in recent filings
- Institutions — 7 new · 4 added · 1 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Boston Scientific Corporation
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 6 → 2026 Q2: 13 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Boston Scientific Corporation
Institutions we track that reported holding this stock in their most recent 13F.
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- Bridgewater Associates0.08% of portfolio · since 2020 Q3
- Point72 Asset Management0.02% of portfolio · since 2021 Q3
- Temasek Holdings (Singapore)0.27% of portfolio · since 2024 Q4
- Tudor Investment Corp0.09% of portfolio · since 2025 Q1
- Maverick Capital2.24% of portfolio · since 2025 Q4
- Glenview Capital ManagementNew this quarter0.09% of portfolio · since 2026 Q2
- Moore Capital ManagementNew this quarter0.12% of portfolio · since 2026 Q2
- Blackstone0.02% of portfolio · held as of 2026 Q2 or earlier
- Capital World Investors0.08% of portfolio · held as of 2026 Q2 or earlier
- Caisse de depot (Quebec)0.19% of portfolio · held as of 2026 Q2 or earlier
- National Pension Service (Korea)0.11% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management1.28% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Boston Scientific. A medical-device company in cardiac, endoscopy, and neuro fields, with stents, catheters, and neuromodulation devices as its mainstays. Regulatory approval and product innovation are the competitive keys.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Boston Scientific Corporation is classified under the Biotech & Health sector. See peers below.
ETFs holding Boston Scientific Corporation
Per SEC N-PORT · 2026-06-30 · by weight · factual
BSX on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
BSX FAQ
What is Boston Scientific Corporation (BSX)?
Boston Scientific. A medical-device company in cardiac, endoscopy, and neuro fields, with stents, catheters, and neuromodulation devices as its mainstays. Regulatory approval and product innovation are the competitive keys.
What sector is Boston Scientific Corporation in?
Boston Scientific Corporation is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
Where can I analyze Boston Scientific Corporation (BSX) stock?
On Stocklore you can see BSX's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.